Erythropoietin regulation of red blood cell production: from bench to bedside and back
暂无分享,去创建一个
M. Weiss | L. Huang | S. Bhoopalan | M. Weiss
[1] 美昭 森山,et al. Erythropoietin , 1972, Reactions Weekly.
[2] W. Fleming,et al. Extrahepatic deficiency of transferrin receptor 2 is associated with increased erythropoiesis independent of iron overload , 2020, The Journal of Biological Chemistry.
[3] S. Hubbard,et al. Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations , 2020, Science.
[4] C. Noguchi,et al. The Many Facets of Erythropoietin Physiologic and Metabolic Response , 2020, Frontiers in Physiology.
[5] D. Swinkels,et al. The multifaceted role of iron in renal health and disease , 2019, Nature Reviews Nephrology.
[6] C. Hillyer,et al. A Unique Epigenomic Landscape Defines Human Erythropoiesis , 2019, Cell reports.
[7] L. Szczech,et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. , 2019, The New England journal of medicine.
[8] Joshua M Kaplan. Roxadustat and Anemia of Chronic Kidney Disease. , 2019, The New England journal of medicine.
[9] T. Lappin,et al. Update on mutations in the HIF: EPO pathway and their role in erythrocytosis. , 2019, Blood reviews.
[10] V. Haase,et al. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. , 2019, Advances in chronic kidney disease.
[11] Samuel L. Wolock,et al. A comprehensive single cell transcriptional landscape of human hematopoietic progenitors , 2019, Nature Communications.
[12] Aviv Regev,et al. Transcriptional States and Chromatin Accessibility Underlying Human Erythropoiesis , 2019, Cell reports.
[13] Asif Hussain,et al. Erythropoietin in perinatal hypoxic-ischemic encephalopathy: a systematic review and meta-analysis , 2019, Journal of perinatal medicine.
[14] D. Baker,et al. Topological control of cytokine receptor signaling induces differential effects in hematopoiesis , 2019, Science.
[15] Hushan Yang,et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. , 2019, Blood advances.
[16] Sohita Dhillon. Roxadustat: First Global Approval , 2019, Drugs.
[17] L. Moore,et al. Human Genetic Adaptation to High Altitude: Evidence from the Andes , 2019, Genes.
[18] W. Rathmell,et al. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers , 2019, The Journal of clinical investigation.
[19] J. McMurray,et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis , 2019, The New England journal of medicine.
[20] P. Greenberg,et al. Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review , 2018, British journal of haematology.
[21] G. Semenza,et al. For their discoveries of how cells sense and adapt to oxygen availability , 2019 .
[22] A. Roetto,et al. The Functional Versatility of Transferrin Receptor 2 and Its Therapeutic Value , 2018, Pharmaceuticals.
[23] M. Narla. Faculty Opinions recommendation of Functional selectivity in cytokine signaling revealed through a pathogenic EPO mutation. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[24] M. Babu,et al. Mechanisms of signalling and biased agonism in G protein-coupled receptors , 2018, Nature Reviews Molecular Cell Biology.
[25] H. Wallweber,et al. Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation , 2018, eLife.
[26] A. Yoshimura,et al. Negative Regulation of Cytokine Signaling in Immunity. , 2018, Cold Spring Harbor perspectives in biology.
[27] T. Ganz,et al. Erythroferrone: An Erythroid Regulator of Hepcidin and Iron Metabolism , 2018, HemaSphere.
[28] R. Skoda,et al. A Gain‐of‐Function Mutation in EPO in Familial Erythrocytosis , 2018, The New England journal of medicine.
[29] Samuel L. Wolock,et al. Population Snapshots Predict Early Hematopoietic and Erythroid Hierarchies , 2018, Nature.
[30] Yukio Nakamura,et al. Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor , 2018, The Journal of experimental medicine.
[31] Sean J Dikdan,et al. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease , 2018, International journal of molecular sciences.
[32] W. Vainchenker,et al. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders , 2018, F1000Research.
[33] Martina Moras,et al. From Erythroblasts to Mature Red Blood Cells: Organelle Clearance in Mammals , 2017, Front. Physiol..
[34] S. Bhandari,et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease , 2017, BMC Nephrology.
[35] A. Perkins,et al. Direct targets of pSTAT5 signalling in erythropoiesis , 2017, PloS one.
[36] P. Solár,et al. Erythropoietin and Its Angiogenic Activity , 2017, International journal of molecular sciences.
[37] M. Delforge,et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes , 2017, Leukemia.
[38] A. Kurtz. Endocrine functions of the renal interstitium , 2017, Pflügers Archiv - European Journal of Physiology.
[39] D. Wojchowski,et al. Governing roles for Trib3 pseudokinase during stress erythropoiesis. , 2017, Experimental hematology.
[40] Jacob C. Ulirsch,et al. Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation , 2017, Cell.
[41] K. Kalantar-Zadeh. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology , 2017, American Journal of Nephrology.
[42] M. Hu,et al. Activating JAK 2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm , 2017 .
[43] A. Nekoui,et al. Erythropoietin and Nonhematopoietic Effects , 2017, The American journal of the medical sciences.
[44] J. Wish,et al. Erythropoietin and Its Cardiovascular Effects , 2017 .
[45] Jingjing Xu,et al. Erythropoietin Rescues Memory Impairment in a Rat Model of Chronic Cerebral Hypoperfusion via the EPO-R/JAK2/STAT5/PI3K/Akt/GSK-3β Pathway , 2017, Molecular Neurobiology.
[46] A. Bigham. Genetics of human origin and evolution: high-altitude adaptations. , 2016, Current opinion in genetics & development.
[47] H. Lodish,et al. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways. , 2016, Experimental hematology.
[48] Clifford Liongue,et al. Evolution of Cytokine Receptor Signaling , 2016, The Journal of Immunology.
[49] James E. Novak,et al. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[50] M. Sahay,et al. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[51] D. Wojchowski,et al. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis , 2016, Expert opinion on therapeutic targets.
[52] T. Ganz,et al. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. , 2016, Seminars in nephrology.
[53] B. Raught,et al. Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling* , 2016, The Journal of Biological Chemistry.
[54] H. Cario,et al. LNK mutations and myeloproliferative disorders , 2016, American journal of hematology.
[55] Jacob C. Ulirsch,et al. Targeted Application of Human Genetic Variation Can Improve Red Blood Cell Production from Stem Cells. , 2016, Cell stem cell.
[56] Jie Huang,et al. Erythropoietin Stimulates Tumor Growth via EphB4. , 2015, Cancer cell.
[57] Raghu Kalluri,et al. Physiology of the Renal Interstitium. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[58] Roberta B. Nowak,et al. A Systems Approach Identifies Essential FOXO3 Functions at Key Steps of Terminal Erythropoiesis , 2015, PLoS genetics.
[59] S. Hemmerich,et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[60] Wei Li,et al. HIF-1α pathway: role, regulation and intervention for cancer therapy , 2015, Acta pharmaceutica Sinica. B.
[61] Irving L. Weissman,et al. Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands , 2015, Cell.
[62] Cheng-Hsien Lu,et al. Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial , 2015, Critical Care.
[63] M. Lidonnici,et al. The second transferrin receptor regulates red blood cell production in mice. , 2015, Blood.
[64] C. Plass,et al. Epo-induced erythroid maturation is dependent on Plcγ1 signaling , 2014, Cell Death and Differentiation.
[65] N. Mohandas,et al. Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E. , 2014, Blood.
[66] A. Sytkowski,et al. Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction , 2014, Front. Immunol..
[67] S. Rivella,et al. IDENTIFICATION OF ERYTHROFERRONE AS AN ERYTHROID REGULATOR OF IRON METABOLISM , 2014, Nature Genetics.
[68] Jie Li,et al. Global transcriptome analyses of human and murine terminal erythroid differentiation. , 2014, Blood.
[69] H. Cario,et al. Polycythaemia‐inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor–EPOR chimeras , 2014, British journal of haematology.
[70] M. Koury. Abnormal erythropoiesis and the pathophysiology of chronic anemia. , 2014, Blood reviews.
[71] A. Mead,et al. Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate , 2014, The Journal of experimental medicine.
[72] J. Palis. Primitive and definitive erythropoiesis in mammals , 2013, Front. Physiol..
[73] Rita Sulahian,et al. Cbl ubiquitination of p85 is essential for Epo-induced EpoR endocytosis. , 2013, Blood.
[74] J. Palis,et al. Erythropoietin critically regulates the terminal maturation of murine and human primitive erythroblasts , 2013, Haematologica.
[75] J. West,et al. Denis Jourdanet (1815-1892) and the early recognition of the role of hypoxia at high altitude. , 2013, American journal of physiology. Lung cellular and molecular physiology.
[76] W. Jelkmann. Physiology and Pharmacology of Erythropoietin , 2013, Transfusion Medicine and Hemotherapy.
[77] Wenli Liu,et al. MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathway. , 2013, Blood.
[78] N. Taylor,et al. Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. , 2013, Blood.
[79] S. Philipsen,et al. Erythropoiesis: development and differentiation. , 2013, Cold Spring Harbor perspectives in medicine.
[80] H. Broxmeyer. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration , 2013, The Journal of experimental medicine.
[81] T. Kasahara,et al. Critical Roles of Myc-ODC Axis in the Cellular Transformation Induced by Myeloproliferative Neoplasm-Associated JAK2 V617F Mutant , 2013, PloS one.
[82] D. Wojchowski,et al. Erythropoietin-directed erythropoiesis depends on serpin inhibition of erythroblast lysosomal cathepsins , 2012, The Journal of experimental medicine.
[83] V. Haase. Regulation of erythropoiesis by hypoxia-inducible factors. , 2013, Blood reviews.
[84] Christian Gieger,et al. Seventy-five genetic loci influencing the human red blood cell , 2012, Nature.
[85] H. Broxmeyer,et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis , 2012, Nature Medicine.
[86] T. Mashino,et al. Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway. , 2012, Cellular signalling.
[87] W. Jelkmann. Functional Significance of Erythrocytes , 2012 .
[88] A. Tzafriri,et al. Stat5 Signaling Specifies Basal versus Stress Erythropoietic Responses through Distinct Binary and Graded Dynamic Modalities , 2012, PLoS biology.
[89] S. Elliott,et al. The effect of erythropoietin on normal and neoplastic cells , 2012, Biologics : targets & therapy.
[90] M. McMullin,et al. A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosis , 2011, American journal of hematology.
[91] Masayuki Yamamoto,et al. Isolation and Characterization of Renal Erythropoietin-Producing Cells from Genetically Produced Anemia Mice , 2011, PloS one.
[92] D. Steensma. Hematopoietic growth factors in myelodysplastic syndromes. , 2011, Seminars in oncology.
[93] S. Watowich. The Erythropoietin Receptor , 2011, Journal of Investigative Medicine.
[94] Peter O. Krutzik,et al. Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons , 2011, Cell.
[95] M. Gassmann,et al. Hypoxia: adapting to high altitude by mutating EPAS-1, the gene encoding HIF-2α. , 2011, High altitude medicine & biology.
[96] W. Jelkmann. Regulation of erythropoietin production , 2011, The Journal of physiology.
[97] Rita Sulahian,et al. Ubiquitination Regulates the Internalization, Endolysosomal Sorting, and Signaling of the Erythropoietin Receptor* , 2010, The Journal of Biological Chemistry.
[98] C. Lacombe,et al. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. , 2010, Blood.
[99] Jinchuan Xing,et al. Genetic Evidence for High-Altitude Adaptation in Tibet , 2010, Science.
[100] Asan,et al. Sequencing of 50 Human Exomes Reveals Adaptation to High Altitude , 2010, Science.
[101] D. Peet,et al. The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. , 2010, Cell metabolism.
[102] L. Huang,et al. Advances in understanding the pathogenesis of primary familial and congenital polycythaemia , 2010, British journal of haematology.
[103] H. Lodish,et al. From stem cell to erythroblast: Regulation of red cell production at multiple levels by multiple hormones , 2010, IUBMB life.
[104] P. Sathyanarayana,et al. Erythropoietin receptor response circuits , 2010, Current opinion in hematology.
[105] S. Solomon,et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.
[106] J. Johnston,et al. A new polycythaemia vera‐associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses , 2009, British Journal of Haematology.
[107] S. Heck,et al. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis , 2009, Proceedings of the National Academy of Sciences.
[108] Chris P. Miller,et al. Evaluating Erythropoietin‐Associated Tumor Progression Using Archival Tissues from a Phase III Clinical Trial , 2009, Stem cells.
[109] H. Lodish,et al. ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. , 2009, Blood.
[110] Ondine Cleaver,et al. Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia. , 2009, Blood.
[111] Doheon Lee,et al. Comparative analysis of the JAK/STAT signaling through erythropoietin receptor and thrombopoietin receptor using a systems approach , 2009, BMC Bioinformatics.
[112] H. Lodish,et al. Intracellular signaling by the erythropoietin receptor , 2009 .
[113] S. Constantinescu. Mechanism of erythropoietin receptor activation , 2009 .
[114] Cheng Luo,et al. Polyhydroxylated fullerene derivative C60(OH)24 prevents mitochondrial dysfunction and oxidative damage in an MPP+‐induced cellular model of Parkinson's disease , 2008, Journal of neuroscience research.
[115] H. Beug,et al. Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. , 2008, Blood.
[116] N. Andrews,et al. Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression. , 2008, Blood.
[117] V. Nizet,et al. Role of the hypoxia inducible factors HIF in iron metabolism , 2008, Cell cycle.
[118] S. Rane,et al. Hematopoietic cytokine receptor signaling , 2007, Oncogene.
[119] David Bryder,et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. , 2007, Cell stem cell.
[120] S. Ghaffari,et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. , 2007, The Journal of clinical investigation.
[121] Mary Frances McMullin,et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. , 2007, Blood.
[122] P. Ratcliffe. HIF-1 and HIF-2: working alone or together in hypoxia? , 2007, The Journal of clinical investigation.
[123] G. Remuzzi,et al. Correction of anemia--payoffs and problems. , 2006, The New England journal of medicine.
[124] Huiman Barnhart,et al. Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.
[125] D. Wojchowski,et al. Lyn kinase promotes erythroblast expansion and late-stage development. , 2006, Blood.
[126] M. Guglin,et al. Cardiovascular Effects of Erythropoietin: Anemia and Beyond , 2006, Cardiology in review.
[127] M. Socolovsky,et al. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. , 2006, Blood.
[128] P. Kopsombut,et al. Bcl-x(L) prevents apoptosis of late-stage erythroblasts but does not mediate the antiapoptotic effect of erythropoietin. , 2005, Blood.
[129] H. Lodish,et al. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. , 2005, Blood.
[130] C. Enns,et al. Diferric transferrin regulates transferrin receptor 2 protein stability. , 2004, Blood.
[131] P. Ghezzi,et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[132] C. Deng,et al. Inactivation of Stat5 in Mouse Mammary Epithelium during Pregnancy Reveals Distinct Functions in Cell Proliferation, Survival, and Differentiation , 2004, Molecular and Cellular Biology.
[133] A. Harris,et al. Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor* , 2004, Journal of Biological Chemistry.
[134] Christopher J. Schofield,et al. Oxygen sensing by HIF hydroxylases , 2004, Nature Reviews Molecular Cell Biology.
[135] D. Hilton,et al. Inhibitors of Cytokine Signal Transduction* , 2004, Journal of Biological Chemistry.
[136] Chris P. Miller,et al. Roles for an Epo Receptor Tyr-343 Stat5 Pathway in Proliferative Co-signaling with Kit* , 2003, Journal of Biological Chemistry.
[137] I. Macdougall,et al. Recombinant erythropoietin in clinical practice , 2003, Postgraduate medical journal.
[138] A. Carrera,et al. The p85 Regulatory Subunit Controls Sequential Activation of Phosphoinositide 3-Kinase by Tyr Kinases and Ras* , 2002, The Journal of Biological Chemistry.
[139] H. Lodish,et al. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. , 2001, Molecular cell.
[140] G. Semenza,et al. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .
[141] J. Ihle,et al. The distal region and receptor tyrosines of the Epo receptor are non‐essential for in vivo erythropoiesis , 2001, The EMBO journal.
[142] H. Lodish,et al. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[143] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[144] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[145] H. Lodish,et al. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. , 2001, Molecular cell.
[146] K. Ozawa,et al. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. , 2000, Blood.
[147] H. Lodish,et al. Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice A Direct Role for Stat5 in Bcl-XL Induction , 1999, Cell.
[148] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[149] H. Beug,et al. A Novel Way to Induce Erythroid Progenitor Self Renewal: Cooperation of c-Kit with the Erythropoietin Receptor , 1999, Biological chemistry.
[150] J. Marine,et al. Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.
[151] H. Lodish,et al. Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[152] J. Iredale,et al. Sites of erythropoietin production. , 1997, Kidney international.
[153] L. Platanias,et al. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1 , 1996, Molecular and cellular biology.
[154] S. Koury,et al. Erythropoietin production by interstitial cells of hypoxic monkey kidneys , 1996, British journal of haematology.
[155] A. Maxwell,et al. LOCALIZATION OF ERYTHROPOIETIN GENE EXPRESSION IN PROXIMAL RENAL TUBULAR CELLS DETECTED BY DIGOXIGENIN‐LABELLED OLIGONUCLEOTIDE PROBES , 1996, The Journal of pathology.
[156] Rudolf Jaenisch,et al. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor , 1995, Cell.
[157] H. Lodish,et al. Interaction of the erythropoietin and stem-cell-factor receptors , 1995, Nature.
[158] G. Semenza,et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[159] T. McKeithan,et al. Kinetic proofreading in T-cell receptor signal transduction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[160] D. Neumann,et al. Intermediates in degradation of the erythropoietin receptor accumulate and are degraded in lysosomes. , 1993, The Journal of biological chemistry.
[161] M. Le Hir,et al. Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[162] M. Fan,et al. The long-term effects of recombinant human erythropoietin on the cardiovascular system. , 1992, Clinical nephrology.
[163] E. Ikkala,et al. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. , 1991, Blood.
[164] N. Casadevall,et al. Erythropoietin: sites of synthesis and regulation of secretion. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[165] S. Antonarakis,et al. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[166] J. Spivak,et al. Erythropoietin is both a mitogen and a survival factor. , 1991, Blood.
[167] M. Koury,et al. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. , 1990, Science.
[168] H. Lodish,et al. Expression cloning of the murine erythropoietin receptor , 1989, Cell.
[169] D. Mason,et al. Isolation and immunocytochemical characterization of human bone marrow stromal macrophages in hemopoietic clusters , 1988, The Journal of experimental medicine.
[170] F. Wendling,et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. , 1988, The Journal of clinical investigation.
[171] M. Koury,et al. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. , 1988, Blood.
[172] C. Ponticelli,et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. , 1987, British medical journal.
[173] M. Koury,et al. Erythropoietin control of terminal erythroid differentiation: maintenance of cell viability, production of hemoglobin, and development of the erythrocyte membrane. , 1987, Blood cells.
[174] C. H. Lin,et al. Cloning and expression of the human erythropoietin gene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[175] E. Goldwasser,et al. Purification of human erythropoietin. , 1977, The Journal of biological chemistry.
[176] D. Hammond,et al. PARANEOPLASTIC ERYTHROCYTOSIS AND ECTOPIC ERYTHROPOIETINS * , 1974, Annals of the New York Academy of Sciences.
[177] E. Goldwasser,et al. Role of the Kidney in Erythropoiesis , 1957, Nature.
[178] A. Erslev,et al. Humoral regulation of red cell production. , 1953, Blood.
[179] K. Reissmann. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. , 1950, Blood.